Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
17 May 2025
| 00:41 | Acute coronary syndrome pre-hospital evaluation and care diffhist +3,767 Basir Gill talk contribs | ||||
16 May 2025
| 23:18 | Upload log Basir Gill talk contribs uploaded File:Care system ACS.png | ||||
15 May 2025
14 May 2025
| 20:45 | User creation log User account Charlotte Casucci talk contribs was created by Alberto Castro Molina talk contribs | ||||
13 May 2025
|
|
22:33 | Umbralisib 2 changes history −33 [Parth Vikram Singh (2×)] | |||
|
|
22:33 (cur | prev) −1 Parth Vikram Singh talk contribs | ||||
|
|
22:30 (cur | prev) −32 Parth Vikram Singh talk contribs | ||||
| N 22:16 | Melphalan flufenamide diffhist +1,001 Parth Vikram Singh talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=melphalan |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Melphalan flufenamide in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline...") | ||||
| 22:15 | Loncastuximab tesirine-lpyl diffhist −37 Parth Vikram Singh talk contribs | ||||
| 21:53 | Sulopenem etzadroxil, probenecid diffhist −536 Parth Vikram Singh talk contribs | ||||
|
|
21:08 | Deuruxolitinib 3 changes history −9,467 [Parth Vikram Singh (3×)] | |||
|
|
21:08 (cur | prev) −1 Parth Vikram Singh talk contribs | ||||
|
|
21:03 (cur | prev) 0 Parth Vikram Singh talk contribs | ||||
|
|
21:03 (cur | prev) −9,466 Parth Vikram Singh talk contribs | ||||
|
|
20:31 | Miplyffa 2 changes history −191 [Parth Vikram Singh (2×)] | |||
|
|
20:31 (cur | prev) −204 Parth Vikram Singh talk contribs | ||||
|
|
20:30 (cur | prev) +13 Parth Vikram Singh talk contribs | ||||
| N 20:12 | Rimegepant diffhist +25,945 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=rimegepant |aOrAn=an |drugClass=antagonist of the calcitonin gene-related peptide receptor |indicationType=treatment |indication='''Acute Treatment of Migraine''' NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults. '''Preventive Treatment of Episodic Migraine''' NURTEC ODT is indicated for the preventive treatment of episodic migraine in...") | ||||
| N 10:30 | Isatuximab diffhist +43,562 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=isatuximab |aOrAn=a |drugClass=monoclonal antibody |indicationType=treatment |indication=SARCLISA is indicated: *in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. *in combination with carfilzomib and dexamethasone, for the t...") | ||||
12 May 2025
| N 22:08 | Osilodrostat diffhist +28,979 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=osilodrostat |aOrAn=a |drugClass=inhibits 11beta-hydroxylase |indicationType=treatment |indication=of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. |adverseReactions=Clinically significant adverse reactions that appear in other sections of the labeling include: *Hypocortisolism *QT Prolongation *Eleva...") | ||||
| N 21:54 | Ozanimod diffhist +59,391 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=ozanimod |aOrAn=a |drugClass=potent S1PR modulator |indicationType=treatment |indication=*relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. *moderately to severely active ulcerative colitis (UC) in adults. |adverseReactions=*Infections *Progressive Multifocal Leu...") | ||||
| m 02:15 | TATA box gene transcriptions diffhist +9 Marshallsumter talk contribs (→Butler TATA box genes) | ||||
11 May 2025
| N 13:37 | Selumetinib diffhist +28,699 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=selumetinib |aOrAn=a |drugClass=selectively inhibiting MEK1 and MEK2 |indication=KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). |adverseReactions=The following clinically significant adverse reactions are described elsewhere in the labeling:...") | ||||